Skip to main content

Truseltiq Side Effects

Generic name: infigratinib

Medically reviewed by Last updated on May 4, 2022.

Note: This document contains side effect information about infigratinib. Some dosage forms listed on this page may not apply to the brand name Truseltiq.

Applies to infigratinib: oral capsule.

Serious side effects of Truseltiq

Along with its needed effects, infigratinib (the active ingredient contained in Truseltiq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking infigratinib:

More common

  • Blindness
  • blurred vision
  • confusion
  • constipation
  • decreased vision
  • depression
  • difficulty in breathing
  • dry eye
  • dry mouth
  • eyelash changes
  • headache
  • incoherent speech
  • increased urination
  • irregular heartbeats
  • loss of appetite
  • metallic taste
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle weakness
  • nausea
  • numbness and tingling around the mouth, fingertips, or feet
  • redness, swelling, or itching of the eyelid
  • redness, swelling, pain, or ulceration of the skin
  • scaling of the skin on the hands and feet
  • seizures
  • stomach cramps
  • thirst
  • tingling of the hands and feet
  • tremor
  • unusual tiredness
  • vomiting
  • weight loss

Less common

  • Chills
  • cough or hoarseness
  • dizziness, lightheadedness, or fainting
  • dry mouth
  • fast heartbeat
  • fever or chills
  • lower back or side pain
  • painful or difficult urination
  • rapid, shallow breathing

Other side effects of Truseltiq

Some side effects of infigratinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Acid or sour stomach
  • belching
  • bloody nose
  • change in taste
  • decreased weight
  • diarrhea
  • difficulty in moving
  • dry skin
  • hair loss, thinning of hair
  • heartburn
  • indigestion
  • lack or loss strength
  • loss of taste
  • muscle pain or stiffness
  • pain in the arms or legs
  • pain in the joints
  • redness or soreness around the fingernails or loosening of the fingernails
  • stomach discomfort, upset, or pain
  • swelling of the hands, ankles, feet, or lower legs
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to infigratinib: oral capsule.


Very common (10% or more): Decreased hemoglobin (53%), decrease lymphocytes (43%), decreased platelets (37%), decreased leukocytes (26%), decreased neutrophils (14%), decreased albumin (24%), increased urate (37%)[Ref]


Very common (10% or more): Arthralgia (32%), pain in extremity (17%)

Common (1% to 10%): Fractures[Ref]


Very common (10% or more): Dry eye (44%), eyelash changes (25%), blurred vision (21%), cataracts (12%)[Ref]


Very common (10% or more): Increased phosphate (90%), decreased phosphate (64%), increased lipase (44%), increased calcium (43%), decreased sodium (41%), decreased calcium (10%), increased potassium (17%), decreased potassium (21%), decrease weight (15%)[Ref]


Very common (10% or more): Increased triglycerides (38%), increased alkaline phosphatase (54%), increased alanine aminotransferase (51%), increased cholesterol (18%), increased bilirubin (24%), increased aspartate aminotransferase (38%), increased lipase (44%)[Ref]


Very common (10% or more): Epistaxis (18%)[Ref]

Nervous system

Very common (10% or more): Fatigue (44%), dysgeusia (32%)[Ref]


Very common (10% or more): Increased creatinine (93%)[Ref]


Very common (10% or more): Edema/peripheral edema (17%)[Ref]


Very common (10% or more): Nail toxicity (57%), alopecia (38%), dry skin (23%), palmar-plantar erythrodysesthesia syndrome (33%)[Ref]


Very common (10% or more): Stomatitis (56), constipation (30%), abdominal pain (26%), dry mouth (25%), diarrhea (24%), vomiting (21%), nausea (19%), dyspepsia (17%)[Ref]


Serious adverse reactions in 2% or more patients included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient. Adverse reactions requiring permanent discontinuation in 1% or more patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.[Ref]


1. "Product Information. Truseltiq (infigratinib)." QED Therapeutics Inc (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.